Literature DB >> 10588171

Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination.

W E Whitehead1.   

Abstract

Subgroups of patients with irritable bowel syndrome (IBS) are likely to respond differently to existing and evolving therapies. The following criteria for subgrouping may be considered: (1) Patients with different predominant bowel habits respond differently to treatment (antidepressants, 5HT3-antagonists, psychotherapy). (2) Postprandial exacerbation of pain or other gastrointestinal symptoms is seen in approximately half of patients with IBS and may identify patients who are more responsive to some classes of drugs (e.g., those targeted at motility). (3) Women appear to respond differently from men to 5HT3-antagonists, and there may be gender differences in gastrointestinal physiology. (4) There is more overlap in the diagnosis of functional dyspepsia and IBS than would be predicted by chance, and both are associated with hyperalgesia to intraluminal distention.

Entities:  

Mesh:

Year:  1999        PMID: 10588171     DOI: 10.1016/s0002-9343(99)00078-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Is the colonic response to food different in IBS in contrast to simple constipation or diarrhea without abdominal pain?

Authors:  Michel Bouchoucha; Ghislain Devroede; Jean-Jacques Raynaud; Cyriaque Bon; Bakhtiar Bejou; Robert Benamouzig
Journal:  Dig Dis Sci       Date:  2011-04-11       Impact factor: 3.199

2.  The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study.

Authors:  Reyhaneh Vejdani; Hamid Reza Mohaghegh Shalmani; Mina Mir-Fattahi; Faranak Sajed-Nia; Morteza Abdollahi; Mohammad Reza Zali; Amir Houshang Mohammad Alizadeh; Ali Bahari; Gholamreza Amin
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

Review 3.  Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials.

Authors:  Xue Shang; Fen-Fen E; Kang-Le Guo; Yan-Fei Li; Hong-Lin Zhao; Yan Wang; Nan Chen; Tao Nian; Chao-Qun Yang; Ke-Hu Yang; Xiu-Xia Li
Journal:  Nutrients       Date:  2022-06-15       Impact factor: 6.706

4.  Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.

Authors:  Jeffrey M Lackner; James Jaccard; Charles Baum
Journal:  Value Health       Date:  2012-11-30       Impact factor: 5.725

5.  Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome.

Authors:  E Guthrie; F Creed; L Fernandes; J Ratcliffe; J Van Der Jagt; J Martin; S Howlett; N Read; J Barlow; D Thompson; B Tomenson
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

6.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

7.  Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study.

Authors:  Michel Dapoigny; Thierry Piche; Philippe Ducrotte; Bernard Lunaud; Jean-Michel Cardot; Annick Bernalier-Donadille
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

Review 8.  Antibiotics for irritable bowel syndrome: rationale and current evidence.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Curr Gastroenterol Rep       Date:  2012-10

9.  Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers.

Authors:  Elsa M Eriksson; Kristina I Andrén; Henry T Eriksson; Göran K Kurlberg
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

10.  Proton pump inhibitors: effective first-line treatment for management of dyspepsia.

Authors:  David A Peura; Jeff Gudmundson; Nancy Siepman; Betsy L Pilmer; James Freston
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.